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Growth factor-induced phenotypic modulation 
Isolated smooth muscle cells in culture do not immediately start dividing, even in a 
medium containing all nutrients required. Before entering the cell cycle, the cells first 
accommodate their phenotype to their new environment. They lose their contractile 
properties and modulate to a proliferative and synthetic phenotype, characterised by 
decreased contractile protein and M3 receptor expression, but enhanced expression 
of PKC and synthetic organelles [1;2]. This process of phenotypic modulation has 
been postulated to occur in vivo during periods of airway inflammation, in view of the 
increased airway smooth muscle (ASM) mass seen in asthmatics which is partly due 
to an increase in cell number [3]. A central role for phenotypic modulation in smooth 
muscle growth is also acknowledged in vascular remodeling. In atherosclerotic 
lesions, neointima formation is accompanied by modulation of smooth muscle cell 
phenotype to favour conditions of growth and extracellular matrix deposition [4]. 
 
ASM phenotypic modulation can be induced by exposing cells to high concentrations 
of fetal bovine serum (FBS). The main disadvantage of studying phenotypic plasticity 
in cell culture is, however, that cell to cell contacts and cell to matrix contacts are 
disrupted. Even at confluence, cell culture cannot mimic the three-dimensional 
context of intact muscle. The extracellular matrix in which the muscle cells are 
embedded has been found of major importance: vascular smooth muscle cells can 
be retained in their contractile phenotype when cultured in laminin-coated flasks or 
on matrigel, which contains solubilized basement membrane proteins [5;6]. In 
addition, human ASM cells cultured on laminin exhibit a contractile phenotype, 
whereas collagen I and fibronectin favour progression to a proliferative and less 
contractile phenotype [7]. 
 
To study the impact of the natural mix of extracellular matrix components on 
phenotypic modulation, Tao et al. cultured ASM cells on top of a ethanol-fixed layer 
of dead ASM cells, reasoning that the complex mix of extracellular matrix proteins 
synthesized by smooth muscle cells would create a more physiological environment 
[8]. They found that cells cultured under such conditions did not lose contractile 
responsiveness to methacholine, suggesting that phenotypic modulation is less 
prominent in this setting. Also, these cells did not spread to the extent that smooth 
muscle cells do when plated on glass and they did not acquire stress fibres. It is 
important to note, however, that the conditions used to create this matrix 
environment (smooth muscle cells only, stimulation with 10 % FBS) preclude a 
proper comparison to intact muscle. 
 
Therefore, we used an organ culture approach in our studies, since this model has 
the advantage of having all endogenous extracellular matrix constituents and cell to 
cell contacts intact. Using this model, we showed that growth factor-induced 
phenotypic modulation can be induced in the intact muscle (Chapter 2). In summary, 
this study demonstrated that treatment of bovine tracheal smooth muscle (BTSM) 
strips with FBS caused a time-dependent (t½ = 2.8 days) decrease in maximal 




completely abrogated, however, even when exposure to FBS was as long as 8 days. 
In addition, muscarinic M3 receptor expression was not affected as this would result 
in a decreased sensitivity of the muscle strip for methacholine. Importantly, growth 
factor (EGF, IGF-1, PDGF)-induced reductions in contractility were also observed. 
These were strongly correlated to their mitogenic responses in unpassaged primary 
cultures of BTSM cells, indicating that the growth factor-induced reductions in 
contractility may have been the consequence of growth-induced phenotypic 
modulation. This is supported by the observation that the reductions in contractility 
were evident for both receptor-dependent (methacholine) and -independent (KCl) 
contractions, suggesting that the effects occurred at the level of contractile protein 
expression or activity.  
 
It is not clear whether the less prominent loss of contractility in organ culture as 
opposed to cell culture is caused by a less prominent phenotypic modulation of each 
individual smooth muscle cell. Presumably, only the fraction of cells that is 
committed to enter the cell cycle, undergoes phenotypic modulation. This concept of 
phenotypic heterogeneity is supported by the observation that regulation of 
contractility is inversely correlated to the mitogenic responses induced by the growth 
factors applied (Chapter 2). Cell division is an all-or-nothing response and the 
preceding switch in phenotype could be considered likewise.  
 
Recently, a similar organ culture approach was used by Moir et al. for human 
bronchioli. Contractility of these rings was similarly sensitive to prolonged (3-6 days) 
FBS exposure, but no major changes in ASM content could be observed in these 
rings nor were there measurable changes in contractile protein expression [9]. The 
contraction regulatory protein calponin was decreased due to serum exposure in 
these rings however, which could be indicative of some degree of phenotypic 
modulation. Of note, calponin expression is more sensitive to phenotypic modulation 
when compared to contractile proteins in cultured canine ASM cells [1].  
 
The study by Moir et al. also showed increases in calponin expression when human 
bronchioli were exposed to D-STIM, a medium formulated to maintain a contractile 
smooth muscle phenotype [9]. This medium is free of serum, which is interesting in 
view of the reported hypercontractility of cultured canine ASM cells upon prolonged 
serum deprivation [10;11]. However, both the mentioned D-STIM and the serum-free 
media used to induce hypercontractility in canine ASM cells contain high amounts of 
insulin (usually 1 µM). In Chapter 3, we demonstrated that organ cultured BTSM 
strips exposed to insulin respond with increased contractility to KCl and 
methacholine, as compared to fresh and serum-free treated BTSM strips. 
Furthermore, cultured BTSM cells pretreated with insulin were found less 
proliferative in response to peptide growth factors (EGF, PDGF, IGF-1), even though 
acute co-treatment of these growth factors with insulin synergistically activated 
proliferation. Thus, this study showed that the effects of insulin on ASM are time-
dependent. Insulin acutely potentiates the mitogenic responses to other growth 
factors, but induces a hypercontractile and hypo-proliferative phenotype upon 




of serum could have been responsible for the hypercontractile ASM phenotype as 
described by others. This observation is supported by studies demonstrating insulin-
induced differentiation of vascular smooth muscle and skeletal muscle [12;13].  
 
Regulation of contractility by Rho-kinase 
Rho-kinase is involved in the regulation of smooth muscle specific gene transcription 
by controlling the subcellular localization of the transcription factor SRF [14;15]. To 
investigate whether these events also take place in intact ASM, we conducted the 
study described in Chapter 4, demonstrating that pretreatment with the Rho-kinase 
inhibitor Y27632 decreased overall contractility of organ cultured BTSM strips. This 
indicates that basal Rho-kinase activity is involved in controling ASM contractility. 
The contribution of Rho-kinase to ASM contraction was not dependent, however, on 
the phenotypic state of the muscle: hypercontractile BTSM strips, pretreated with 
insulin for 8 days and hypocontractile BTSM strips, pretreated with FBS for 8 days 
were equally susceptible to Rho-kinase inhibition for their contractile responses to 
methacholine and KCl as compared to serum-free pretreated controls.  
 
Since Rho-kinase might also be involved in phenotypic modulation induced by 
growth factors, we studied the effects of Y27632 on PDGF-induced proliferation and 
PDGF-induced reductions in contractility as well. The latter processes were all 
completely insensitive to Y27632, in contrast to inhibitors of p38, p42 and p44 MAPK 
and PI 3-kinase. This supports the concept that the reciprocal relationship between 
contractility and growth (cf. Chapter 2) is prompted by growth-induced phenotypic 
modulation. In addition, the study described in Chapter 4 showed that Rho-kinase 
inhibition may result in an equally less contractile phenotype as observed for growth 
factors, without the concomitant detrimental effects on ASM remodeling, 
 
In turn, this may suggest that growth factors do not activate RhoA and Rho-kinase, 
which contrasts to the results presented in Chapter 5, in which growth factor-induced 
contraction (IGF-1, angiotensin II) was shown to be extremely dependent on Rho-
kinase in human bronchi. These apparently conflicting results are most likely 
explained by species differences as the growth factor applied in Chapter 4 (PDGF) 
does not induce BTSM contraction (unpublished observations). It can therefore not 
be excluded that Rho-kinase is able to counteract growth factor-induced reductions 
of human ASM contractility. The observed maintenance of contractility by Rho-
kinase in Chapter 4 is nonetheless of potential importance in relation to chronic 
changes in ASM function in asthma. Rho-kinase dependent contraction has been 
reported to be increased in repeatedly allergen-challenged Brown-Norway rats [16]. 
This increase was accompanied by increases in RhoA protein expression, which 
suggests that repeated allergen challenge could also evoke increased contractility 
through such a mechanism.  
 
Activation of Rho-kinase has been reported to occur upon stimulation of excitatory 
GPCRs [17]. In addition, although Rho-kinase is known to be activated by growth 




pronounced [18]. Surprisingly therefore, histamine did not rely at all on Rho-kinase 
for its contraction whereas growth factor induced contraction was completely 
abolished (Chapter 5). This shows that kinase activation status does not necessarily 
have to parallel the impact on the physiological response. Most likely the 
transduction reserve of inositol-1,4,5-triphosphate generated by histamine is 
sufficient to overcome the absence of Rho-kinase mediated signalling. Weaker 
contractile agonists such as growth factors on the other hand, need all the 
transductional support they can get.  
 
Regulation of contractility by GPCRs 
Since GPCR agonists activate Rho-kinase, one might expect that prolonged 
treatment of BTSM strips with a GPCR agonist would increase contractility. As 
described in Chapter 6, however, prolonged treatment with methacholine 
dramatically decreased contractility and contractile protein expression (sm-α-actin, 
sm-MHC); these reductions in contractility and contractile protein expression were 
concentration dependent. However, the methacholine-induced reduction in 
contractility was not synergistic with the PDGF-induced reduction in contractility; nor 
was the decreased contractility accompanied by an increase in proliferative capacity, 
indicating that the methacholine-induced effects are distinct from the classical 
phenotype ´switch´ induced by growth factors. Likewise, these methacholine-induced 
effects did not rely on signalling pathways involving PI 3-kinase or MAPK. Rather, a 
prolonged elevation of  [Ca2+]i appeared to be responsible for the decrease in overall 
contractility, as selective elevation of cytosolic [Ca2+] by KCl could mimic the strong 
response induced by methacholine. It is not known whether these effects of 
methacholine represent physiologically relevant processes, since prolonged 
pretreatment with relatively high concentrations were required. In addition, 
phenotypic modulation of smooth muscle cells due to allergen-induced growth might 
alter the methacholine-induced signalling characteristics, including the regulation of 
[Ca2+]i homeostasis. Nevertheless, the results presented in Chapter 6 imply that in 
phenotypically contractile ASM cells, direct stimulation with GPCR agonists is not 
likely to induce a hypercontractile phenotype. 
 
These effects of GPCR agonists also provide a possible explanation for why the use 
of FBS in organ cultured smooth muscles has often failed to produce results that 
support a role for growth-induced phenotypic modulation in organ culture. FBS is a 
classical source for growth factors but also contains insulin and GPCR agonists like 
serotonin, which are responsible for the acute contractile effects of serum [19]. In the 
organ cultured rat renal artery, no effect of prolonged treatment with serum, 
decreasing contractility, could be demonstrated [19]. However, both in the human 
bronchiolus [9], rat tail artery [20], guinea pig ileum [21] and canine colon [22], 
treatment with FBS dramatically reduced contractility when compared to the absence 
of serum, although force responses still deteriorated over time in the absence of 
serum in some of these studies. In the rat tail artery and the guinea pig ileum, this 
serum-induced reduction of contractility appeared to be related to continuously 




verapamil could partially reverse the observed effects [21;23]. In addition, serum 
induced mitogenesis in these preparations appeared to be independent from its 
effects on contractility as verapamil did not inhibit the serum-induced incorporation of 
[3H]thymidine. It should be noted though that even in the presence of verapamil 
some reduction in contractility persists [23], which is quantitatively comparable to the 
decrease in contractility observed by us due to growth factor exposure (Chapter 2). 
This shows that the treatment with serum in these preparations may have caused 
both GPCR / Ca2+ dependent reductions in contractility, comparable to our 
observations for methacholine (Chapter 6), as well as growth factor-induced 
phenotypic modulation.  
 
Contractile agonists as growth factors 
Even though the above mentioned results suggest that GPCR agonists are not likely 
to affect BTSM phenotype in a way similar to growth factors, contractile GPCR 
agonists may on the other hand affect ASM proliferation. Excitatory GPCR agonists 
were first recognized as potential contributors to the increase of ASM mass in 
asthma in 1990, when Panettieri et al. found that histamine could increase canine 
ASM cell number in a concentration-dependent fashion and to a similar extent as 10 
% FBS [24]. Since then, the mitogenic responses to a vast number of GPCR 
agonists have been characterised (Table 11.1). Despite of the reported mitogenic 
effects of histamine, GPCR agonists in general are not effective or less effective 
compared to growth factors. However, they are generally considered effective in 
augmenting growth-factor induced proliferative responses. 
 
This matches our results presented in Chapter 7. In this study, we demonstrated that 
the GPCR agonist methacholine (a derivative of acetylcholine) is not mitogenic for 
BTSM cells by itself, but concentration dependently augments PDGF-induced ASM 
proliferation. This mitogenic synergism was dependent on the cell culture stage used. 
It could be observed only in unpassaged BTSM cells, still functionally expressing Gq 
coupled M3 receptors, whereas higher cell culture stages, not expressing M3 
receptors, did not have mitogenic responses to growth factors at all. The suggested 
relationship between Gq coupled M3 receptors and mitogenic synergism was 
confirmed by the observation that the muscarinic receptor antagonists 4-DAMP and 
DAU5884, applied in M3 selective concentrations, completely abrogated these 
responses. Notably, the Gi coupled muscarinic M2 receptor was not at all involved, 
as the muscarinic M2 receptor selective antagonist gallamine was without effect. 
 
In line with these results, the study described in Chapter 8 demonstrates that the 
GPCR agonist bradykinin is not mitogenic by itself, but concentration-dependently 
potentiates the response to the peptide growth factor EGF in BTSM cells. This effect 
was mediated by the bradykinin B2 receptor, which is a Gq coupled receptor. Further 
downstream, this effect appeared to be caused by conventional PKC iso-enzymes, 
as the synergistic responses were sensitive to both the pan-specific PKC inhibitor 
GF109203X and the conventional iso-enzyme specific inhibitor Gö6976. PKC-




latter enzymes were not activated synergistically by bradykinin and EGF. Therefore, 
the results from this study demonstrate that parallel rather than consecutive 
activation of conventional PKC iso-enzymes and p42/p44 MAP kinase may be 
responsible for the synergistic mitogenic response of a Gq coupled receptor agonist 
and a growth factor. 
 
Table 11.1 Effects of contractile GPCR agonists on ASM proliferation 


















Serotonin  Bovine   [35] 
LTD4  Human Human  [36] 





Neurokinin A  Rabbit   [39] 
Substance P Rabbit 
Human 









 Human  [41-43] 
LPA Human  Human  [28] 
Bradykinin Human Bovine 
Human 
Bovine  [30;44] 
Chapter 8 
 
An important question that arises from the observations made in Chapters 7 & 8 is 
what underlies this apparent effectiveness of Gq coupled receptor as opposed to Gi, 
coupled receptors particularly because it has previously been postulated that Gi 
coupled receptor agonists are more mitogenic compared to Gq coupled receptor 
agonists. This postulate related to studies describing that Gi mediated activation of 
Ras is more effective than Gq mediated activation and to the observation that ASM 
mitogenesis is often pertussis toxin sensitive [25-28]. The selectivity of pertussis 
toxin for Gi may be considered questionable, however: pertussis toxin is known to 
inhibit mitogenesis to a variety of stimuli, irrespective of their selectivity to Gi, Gq (e.g. 
substance P, bradykinin) or even receptor tyrosine kinases (e.g. PDGF) [29-31]. In 
addition, pertussis toxin treatment has been described to downregulate the 




This has important implications, as synergistic induction of mitogenesis by the 
GqPCR agonist bradykinin is dependent on conventional PKC iso-enzymes (Chapter 
8). Furthermore, selective stimulation of receptors known to couple to Gi is 
necessarily not mitogenic, as observed by us for the M2 receptor in Chapter 7. 
 
Another important question is why some GPCR agonists are mitogenic and others 
not. For instance, muscarinic receptor agonists are generally found to be ineffective 
by themselves, which is desirable as the tonic presence of acetylcholine under 
normo-physiological conditions should not result in excessive airway narrowing over 
time. In contrast, thrombin is highly mitogenic (Table 11.1), but present only during 
periods of wound healing when proliferation of smooth muscle is required. Since 
thrombin is one of the most effective mitogenic GPCR agonists, it could be 
envisaged that its capability to activate multiple G proteins (Gi, Gq, G12/13) induces 
‘auto-synergy’. This is illustrated by the fact that two GPCR agonists can respond in 
a synergistic mitogenic fashion, which is more profound when Gi and Gq coupled 
receptor agonists are combined [28]. However, methacholine activates Gi and Gq as 
well, yet is not mitogenic by itself and dependent on Gq coupled M3 receptors only 
for it synergistic mitogenic response (Chapter 7). In addition, recent evidence 
suggests that thrombin is not even dependent on PAR receptors for its mitogenic 
effect [45]. A selective focus on thrombin as a model for GPCR agonists in general is 
therefore not completely appropriate.  
 
Others have considered the possibility that differences in signaling kinetics may 
underlie the discrepancy between mitogenic and non-mitogenic GPCR agonists. 
This approach appears to be more successful: several studies have indicated a 
requirement for prolonged p42/p44 MAPK activation for mitogenesis in both human 
and bovine ASM [29;35;46], irrespective of the type of stimulus applied (GPCR 
agonist, RTK agonist or kinase activator). Also in Chapter 8 we showed that the 
transient p42/p44 MAP kinase activation by bradykinin was not mitogenic, whereas 
the sustained PMA-induced p42/p44 MAP kinase activation resulted in the induction 
of mitogenesis. The key to this stimulus-specificity was the differential activation of 
PKC isozymes: selective inhibition of conventional PKC isozymes by Gö6976 could 
fully inhibit bradykinin-induced p42/p44 MAPK activation, but had not even the 
slightest effect on PMA-induced responses. GF109203X however, which inhibits 
both conventional and novel PKCs, could fully inhibit the PMA effects, which 
suggests the involvement of novel PKC isozymes [47]. It would be interesting to 
investigate this agonist-specificity for mitogenic and non-mitogenic GPCR agonists 
as this may provide insight in the role that these PKC isozymes have in the kinetics 
of p42/p44 MAP kinase activation.  
 
Nevertheless, conventional PKC isozymes appear to be sufficient for a synergistic 
interaction with growth factors in view of the bradykinin-induced effects in 
combination with EGF. Moreover, the synergistic activation of proliferation is not 
accompanied by a synergistic activation of p42/p44 MAP kinase, as demonstrated 




and GPCR-induced potentiation of growth-factor induced proliferation are 
mechanistically completely different effects.  
 
Importantly, both ASM phenotypic plasticity and the synergistic mitogenic interaction 
of GPCR agonists with growth factors reported in the previous Chapters may also 
occur in vivo, as described in Chapter 9. In a guinea pig model of ongoing asthma, 
repeated allergen challenges were shown to induce ASM hyperplasia in the non-
cartlaginous airways and to result in phenotypically hypercontractile ASM cells in the 
cartilaginous airways. Moreover, the long-acting muscarinic receptor antagonist 
tiotropium bromide could inhibit allergen-induced ASM hyperplasia, demonstrating 
that endogenous acetylcholine contributes to ASM growth in vivo presumably 
through mechanisms similar to those observed in vitro. Moreover, the other features 
of allergen-induced airway smooth muscle remodeling, being the increases in 
contractility (tracheal ring preparations) and the increases in contractile protein 
expression (lung homogenates) were also reduced by treatment with tiotropium 
bromide. These results for the first time indicate that endogenous ACh may be 
involved in allergen-induced airway remodelling in vivo. Since prolonged neuronal 
and non-neuronal release of ACh may be induced by various inflammatory 
mediators as observed in asthma and COPD, a role for ACh in airway remodelling 
should be envisaged, which is elaborated on in Chapter 10. 
Taken together, the studies described in this thesis have revealed that: 
• Phenotypic plasticity of airway smooth muscle is no epi-phenomenon of cell 
culture settings, but occurs in organ-cultured intact airway smooth muscle 
preparations in response to growth factors, as well as in vivo in response to 
repeated allergen challenges (Chapters 2 & 9). 
• Insulin is able to induce a hypercontractile airway smooth muscle phenotype 
(Chapter 3). 
• Phenotypic modulation of airway smooth muscle induced by growth factors 
is dependent on pathways involving p38, p42 and p44 MAP kinase, as well 
as PI 3-kinase, but not Rho-kinase (Chapters 2 & 4)  
• Basal Rho-kinase activity is involved in the maintenance of airway smooth 
muscle contractility (Chapter 4).  
• Rho-kinase is a major contributor to growth factor-induced airway smooth 
muscle contraction (Chapter 5). 
• Long-term treatment of intact airway smooth muscle with GPCR agonists 
such as methacholine decreases contractility and contractile protein 
expression through mechanisms presumably involving prolonged elevations 
of cytosolic [Ca2+]. Of importance, this modulation of smooth muscle 
contractility by methacholine does not involve the phenotype ´switch´ as it is 
not accompanied by increases in proliferative capacity (Chapter 6).   
• GPCR agonists, such as methacholine and bradykinin, are generally not 
mitogenic by themselves but are effective in potentiating growth factor-
induced proliferation, both in vitro and in vivo (Chapters 7 - 9). M3 
(methacholine) and B2 (bradykinin) receptors are responsible for this 




which implicates a more prominent role for Gq as compared to Gi coupled 
receptors (Chapters 7 & 8).  
• Activation of novel but not of conventional PKC iso-enzymes leads to 
sustained p42/p44 MAP kinase activation and proliferation of airway smooth 
muscle (Chapter 8). 
• Parallel rather than consecutive activation of PKC and p42/p44 MAPK 
appear to be crucially important in the regulation of proliferation synergy by a 
GPCR agonist and a growth factor (Chapter 8). 
• The long-acting muscarinic receptor antagonist tiotropium bromide 
attenuates airway smooth muscle remodeling (increased contractility, 
contractile protein expression and airway smooth muscle content) induced 
by repeated allergen challenges in a guinea pig model of ongoing asthma, 
suggesting a significant role for  endogenous acetylcholine in the 
development and/or progression of chronic asthma (Chapter 9). 
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